Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of DNN.22.17.036 in Male Androgenetic Alopecia
NCT06355856Phase 4Not yet recruiting
- Sponsor
- Aché Laboratórios Farmacêuticos
- Start
- Apr 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of DNN.22.17.036 in androgenetic alopecia (AGA) (2 arms), sponsored by Aché Laboratórios Farmacêuticos. Primary endpoint: Percentage variation of hairs in the hair loss phase at 180 days. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
DNN.22.17.036
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT06355856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06355856.